Source: International Congress 2019 – Translational aspects of idiopathic interstitial pneumonia
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
G. Lee (Seongnam, Republic of Korea), S. Kang (Seongnam, Republic of Korea), J. Ryou (Seongnam, Republic of Korea), J. Lim (Seongnam, Republic of Korea), Y. Lee (Seongnam, Republic of Korea). Late Breaking Abstract - BBT-877, a Potent Autotaxin Inhibitor in Clinical Development to Treat Idiopathic Pulmonary Fibrosis. 1293

Member's Comments

No comment yet.

Related content which might interest you: Development Of A Machine Learning Combination With Deep Learning For Diagnosing Idiopathic Pulmonary Fibrosis In Chronic Interstitial Lung Disease Source: Virtual Congress 2020 – Predictive markers of progression in connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis Year: 2020 A new Humanized Mouse Model for Idiopathic Pulmonary Fibrosis and Effects of Nintedanib Treatment Source: International Congress 2018 – Progress in basic and translational research on idiopathic interstitial pneumonias Year: 2018 Treatment of Idiopathic Pulmonary Fibrosis - Evidence to Decision Frameworks Source: Guideline 2015 Year: 2015 Late Breaking Abstract - Long-term Effect of Pulmonary Rehabilitation under Nintedanib treatment in Idiopathic Pulmonary Fibrosis (FITNESS study) Source: Virtual Congress 2021 – ALERT: Asthma in adult, in children and ILDs Year: 2021 Evaluation of Idiopathic Pulmonary Fibrosis therapies, Pirfenidone and Nintedanib, in a Human Experimental Model of Fibrosis Source: International Congress 2019 – Translational aspects of idiopathic pulmonary fibrosis Year: 2019 A First-in-Class PRS Inhibitor, DWN12088, as a Novel Therapeutic Agent for Systemic Sclerosis and Associated Interstitial Lung Disease Source: Virtual Congress 2021 – Exploring the phenotypic heterogeneity across rare diffuse parenchymal lung diseases Year: 2021 Treatment of Idiopathic Pulmonary Fibrosis - Executive Summary Source: Guideline 2015 Year: 2015 Clinical Features and Prognosis of Acute exacerbation of Connective Tissue Diseases Associated Pulmonary Fibrosis------ Comparision with Idiopathic Pulmonary Fibrosis Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment Year: 2017 Prevalence and Characteristics of Patients Receiving Antifibrotic Therapy for Idiopathic Pulmonary Fibrosis Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries Year: 2020 Modes of Disease Progression in Different Forms of Interstitial Lung Disease with Usual Interstitial Pneumonia Histology in Patients with Idiopathic and Non-idiopathic Etiologies - A Single Center Experience Source: International Congress 2019 – Immune-mediated interstitial lung diseases: from bench to bedside Year: 2019 Clinical Correlates of Physical Activity in Idiopathic Pulmonary Fibrosis (IPF) Source: International Congress 2019 – Pulmonary rehabilitation for non-obstructive lung diseases Year: 2019 Late Breaking Abstract - Endothelial Cell-Specific Anticoagulation Reduces Inflammation in a Mouse Model of ALI Source: International Congress 2017 – Anti-inflammatory and pro-repair mediators in acute lung injury Year: 2017 Nitrofurantoin Induced Pulmonary Fibrosis: A Case Series Source: Virtual Congress 2021 – Clinical evolution, management and outcomes of patients with rare diffuse parenchymal lung diseases Year: 2021 Late Breaking Abstract - Clinical Efficacy and Safety of Macitentan Transitioned from Bosentan in Patients with Pulmonary Arterial Hypertension Source: International Congress 2018 – Molecular mechanisms and treatment of pulmonary hypertension Year: 2018 Late Breaking Abstract - Balloon Pulmonary Angioplasty for the Treatment of Non Operable Chronic Thromboembolic Pulmonary Hypertension – Initial experience of a Belgian Center Source: International Congress 2018 – Chronic thromboembolic pulmonary hypertension Year: 2018 Late Breaking Abstract - TriOptimize VIII – Improvement of Lung Function with Extrafine Single Inhaler Triple Therapy – Analysis of Response Patterns by Prior Treatment from a Real-World Study. Source: Virtual Congress 2020 – Pharmacological management of COPD Year: 2020 Late Breaking Abstract - Abdominal Muscle Function During Spontaneous Breathing Trials to Predict Extubation Failure Source: Virtual Congress 2020 – Novel findings regarding acute respiratory distress syndrome, extra corporeal membrane oxygenation and weaning from mechanical ventilation Year: 2020 Late Breaking Abstract - CPAnet Registry – An International Chronic Pulmonary Aspergillosis Registry Source: Virtual Congress 2020 – Airway infection: the microbiome and beyond Year: 2020 Aerobic and Breathing Exercises Improve Dyspnea, Exercise Capacity and Quality of Life in Idiopathic Pulmonary Fibrosis Patients: Systematic Review and Meta-Analysis. Source: International Congress 2019 – Treatment and prognosis of idiopathic interstitial pneumonia Year: 2019 Breath Biomarkers in Idiopathic Pulmonary Fibrosis: A Systematic Review Source: International Congress 2018 – News on the diagnosis of idiopathic interstitial pneumonia Year: 2018